A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors
Recruiting in Palo Alto (17 mi)
+14 other locations
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Academic
Recruiting
Sponsor: TScan Therapeutics, Inc.
No Placebo Group
Trial Summary
What is the purpose of this trial?TScan Therapeutics is developing cellular therapies across multiple solid tumors in which autologous participant-derived T cells are engineered to express a T cell receptor that recognizes cancer-associated antigens presented on specific Human Leukocyte Antigen (HLA) molecules. The purpose of this screening study is to collect samples to conduct HLA genotyping, HLA Loss of Heterozygosity (LOH) and expression of Tumor-associated Antigens (TAA) testing. These results will be used to determine if subjects meet the eligibility criteria for these parameters and could potentially be enrolled in a TScan clinical treatment study.
Eligibility Criteria
Inclusion Criteria
Willing and able to provide written informed consent.
Male or female aged ≥18 years at the time of signing the informed consent.
Head and neck cancer
+7 more
Participant Groups
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
University of Minnesota, Masonic Cancer CenterMinneapolis, MN
OU Health Stephenson Cancer CenterOklahoma City, OK
Karmanos Cancer InstituteDetroit, MI
The Cleveland ClinicCleveland, OH
More Trial Locations
Loading ...
Who Is Running the Clinical Trial?
TScan Therapeutics, Inc.Lead Sponsor